Chris Viehbacher
Biogen tapped Viehbacher as CEO for his ability to rebuild post their looming patent cliff.
Viehbacher is the rare pharma executive who has a keen understanding of the complexities involved in running a multibillion-dollar global pharma business as well as a deep appreciation for the value of innovation.
Viehbacher’s ability to diversify assets by deftly navigating M&A and refocusing R&D, combined with rigorous cost control, will enable him to lead Biogen to sustainable, long-term growth.
By submitting this form, you are agreeing to ManagementTrack’s Privacy Policy. You can choose to opt out of marketing or advertising emails using the ‘unsubscibe’ link included in our emails.
The best
The best
The best
Our investigative journalists interview the top former colleagues of the CEOs you care about.
Our former buysider analysts summarize the key strengths & weaknesses, past successes & failures, and ability to drive value going forward.
You get access to the actual anonymized transcripts and insights.